期刊文献+

静脉铁剂影响肾性贫血小鼠组织中T淋巴细胞亚群分布的实验研究 被引量:1

Effect of Intravenous Iron Injection on Distributions of T Lymphocytes Subsets,Experimental Research in Renal Anemia Mice
下载PDF
导出
摘要 目的:观察并比较低分子右旋糖酐铁、蔗糖铁两种常用的静脉铁剂对肾性贫血小鼠不同组织中T淋巴细胞亚群分布的影响。方法:构建肾性贫血小鼠模型,尾静脉注射静脉铁剂24h后,分离小鼠外周血、肝脏、脾脏、肾脏中单个核细胞,利用流式细胞仪分析辅助性T(Thelp、T)细胞、抑制性T(Ts、Ts)细胞、自然杀伤(natural killer,NK)细胞在不同组织中的分布。结果:接受静脉铁剂后,小鼠肝脏和肾脏中Th细胞的比例下调,差异有统计学意义(P<0.05),同时铁剂在脾脏、肝脏和肾脏中还不同程度地提高T细胞向Ts细胞分化的比例,同样差异有统计学意义(P<0.05)。另外,静脉铁剂还抑制了外周血、肝脏和脾脏中NK细胞的分布,差异有统计学意义(P<0.05)。结论:静脉铁剂可以单独也可协同尿毒症一起导致机体多脏器中免疫微环境的紊乱。 Objective:To compare the effects of two commercial intravenous iron agents (Low molecular weight iron dextran and iron sucrose) on distributions of T lymphocytes subsets from experimental renal anemia mice.Methods:Twenty-four hours later than iron administration via tail vein,the mononuclear cells were separated from peripheral vein blood,liver,spleen and kidney in experimental renal anemia mice.The ratios of helper T lymphocytes (Th), suppress T lymphocytes (Ts) and natural killer cells (NK) in difference tissues were assayed by flow cytometry.Results:After the iron injection, the ratios of Th cells in liver and kidney were decreased significantly (P0.05),meanwhile the distributions of Ts in spleen, liver and kidney were also elevated (P0.05).And then the NK populations in peripheral blood, liver and spleen were much less than that before iron supplement(P0.05).Conclusion:Combination with uremic status or alone, the intravenous iron agent could be result of multiple organs immune dysfunction.
出处 《中国中西医结合肾病杂志》 2011年第11期963-966,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
基金 2008年第二军医大学创新能力培养计划项目(No.2008066)
关键词 静脉铁剂 T淋巴细胞 免疫紊乱 Intravenous iron agent T Lymphocytes Immune dysfunction
  • 相关文献

参考文献15

  • 1于瑞波,张传方.静脉补铁治疗腹膜透析患者肾性贫血的临床研究进展[J].中国中西医结合肾病杂志,2010,11(2):186-188. 被引量:4
  • 2Zager RA.Johnson AC,Hanson SY.Parenteral iron nephrotoxicity:potential mechanisms and consequences.Kidney Int,2004,66(1):144-56. 被引量:1
  • 3Kuo KL,Hung SC,Wei YH,et al.Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients.J Am Soc Nephrol,2008,19(9):1817-1826. 被引量:1
  • 4Zager RA.Parenteral iron treatment induces MCP-1 accumulation in plasma,normal kidneys,and in experimental nephropathy.Kidney Int,2005,68(4):1533-1542. 被引量:1
  • 5Pai AB,Norenberg J,Boyd A,et al.Effect of intravenous iron supplementation on hepatic cytochrome P450 3A4 activity in hemodialysis patients:a prospective,open-label study.Clin Ther,2007,29(12):2699-2705. 被引量:1
  • 6Breborowicz M,Polubinska A,Tam P,et al.Effect of iron sucrose on human peritoneal mesothelial cells.Eur J Clin Invest,2003,33(12):1038-1044. 被引量:1
  • 7Auerbach M,Al TK.Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.Kidney Int,2008,73(5):528-530. 被引量:1
  • 8Jaber BL.Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.Kidney Int,2008,73(5):511-512. 被引量:1
  • 9Agarwal R.Proinflammatory effects of iron sucrose in chronic kidney disease.Kidney Int,2006,69(7):1259-1563. 被引量:1
  • 10Deicher R,Ziai F,Cohen G,et al.High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity.Kidney Int,2003,64(2):728-736. 被引量:1

二级参考文献19

  • 1赵占正,程根阳,肖静,王沛,刘章锁.静脉滴注足量右旋糖酐铁治疗腹膜透析病人贫血[J].中国新药与临床杂志,2005,24(9):750-752. 被引量:2
  • 2唐雅文,黄小妹,李红兵.静脉补铁对维持性血透患者生活质量的影响[J].中国中西医结合肾病杂志,2005,6(12):722-724. 被引量:4
  • 3郭志勇,李保春,袁伟杰,郭云珊,房振宇,于蕾.静脉用右旋糖酐氢氧化铁注射液治疗腹膜透析患者肾性贫血的临床研究[J].中国血液净化,2006,5(5):238-241. 被引量:5
  • 4Singh H,Reed J,Noble S,et al.United States Iron Sucrose (Venofer) Clinical Trials Group.Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesisstimulating agents for anemia:a randomized,controlled trial.Clin J Am Soc Nephrol,2006,1 (3):475-482. 被引量:1
  • 5Li H,Wang SX.Intravenous iron sucrose in peritoneal dialysis patients with renal anemia.Perit Dial Int,2008,28(2):149-154. 被引量:1
  • 6Aggarwal HK,Tziviskou E,Bellizzi V,et al.Prolonged administration over 6h of large doses of intravenous iron saccharate (500 mg)prevents severe adverse reactions in peritoneal dialysis patients.Perit Dial Int,2002,22(5):636-637. 被引量:1
  • 7National Kidney Foundation:K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Diseasw:update 2000.Am J Kidney Dis,2001,37(1 Suppl 1):s182-s238. 被引量:1
  • 8DeVecchi AF,Novembrino C,Lonati S,et al.Two differentmodalities of iron gluconateiv.Administration:effectson iron,oxidative and inflammatory status in peritoneal dialysis patients.Nephrol Dial Transplant,2007,22(6):1709-1713. 被引量:1
  • 9Chertow GM,Mason PD,Vaage-Nilsen O,et al.Update on adverse drug events associated with parenteral iron.Nephrol Dial Transplant,2006,21 (2):378-382. 被引量:1
  • 10Bailie GR,Johnson CA,Mason NA.Parenteral iron use in the management of anemia in end-stage rena disease patient.Am J Kidney Dis,2000,35 (1):1-12. 被引量:1

共引文献3

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部